Ubiquitination is a crucial post-translational modification process where the small protein ubiquitin is attached to target proteins, marking them for degradation or altering their function. This process is vital for many biological pathways, including cell cycle regulation, DNA repair, protein quality control, and immune response. Aberrant ubiquitination has been linked to various diseases, particularly cancer. Tumor cells often exploit the ubiquitin system to promote their growth, evade immune surveillance, or resist cell death. This includes the design of small molecule drugs capable of inhibiting key ubiquitination enzymes, particularly those E3 ligases involved in tumor growth and maintenance. Therefore, understanding how ubiquitination contributes to tumor development and how to intervene in this process is an important topic in the field of cancer therapy.
This Research Topic aims to illuminate the intricate role of ubiquitination in the initiation, growth, and spread of tumors, as well as to explore its therapeutic potential. We aim to decipher the mechanisms through which ubiquitination modulates the stability and activity of proteins pivotal in cancer biology, such as tumor suppressors and oncoproteins. Furthermore, we seek to understand how dysregulation of the ubiquitin system contributes to tumorigenesis and how current and emerging drugs that target this pathway can be harnessed for innovative cancer treatments, potentially offering new avenues for intervention and improved patient outcomes.
Potential subthemes of this Research Topic include, but are not limited to:
• Interdisciplinary studies between molecular biology, cell biology, immunology, and pathology, especially those focused on the ubiquitination pathway and mechanisms of tumorigenesis.
• Pharmacology and chemical drug related content, dedicated to developing small molecule inhibitors against ubiquitination enzymes.
• Oncology clinical content, interested in the impact of ubiquitination on patient treatment responses.
• Research content of bioinformatics application, skilled in analyzing high-throughput data of ubiquitination substrates and related pathways. (Purely bioinformatics content is outside the scope of this topic)
The topic of this study covers all tumor types, and the study of non-tumor diseases is not within the scope of this study. Reviews, article, and case reports are the main article types.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Ubiquitination is a crucial post-translational modification process where the small protein ubiquitin is attached to target proteins, marking them for degradation or altering their function. This process is vital for many biological pathways, including cell cycle regulation, DNA repair, protein quality control, and immune response. Aberrant ubiquitination has been linked to various diseases, particularly cancer. Tumor cells often exploit the ubiquitin system to promote their growth, evade immune surveillance, or resist cell death. This includes the design of small molecule drugs capable of inhibiting key ubiquitination enzymes, particularly those E3 ligases involved in tumor growth and maintenance. Therefore, understanding how ubiquitination contributes to tumor development and how to intervene in this process is an important topic in the field of cancer therapy.
This Research Topic aims to illuminate the intricate role of ubiquitination in the initiation, growth, and spread of tumors, as well as to explore its therapeutic potential. We aim to decipher the mechanisms through which ubiquitination modulates the stability and activity of proteins pivotal in cancer biology, such as tumor suppressors and oncoproteins. Furthermore, we seek to understand how dysregulation of the ubiquitin system contributes to tumorigenesis and how current and emerging drugs that target this pathway can be harnessed for innovative cancer treatments, potentially offering new avenues for intervention and improved patient outcomes.
Potential subthemes of this Research Topic include, but are not limited to:
• Interdisciplinary studies between molecular biology, cell biology, immunology, and pathology, especially those focused on the ubiquitination pathway and mechanisms of tumorigenesis.
• Pharmacology and chemical drug related content, dedicated to developing small molecule inhibitors against ubiquitination enzymes.
• Oncology clinical content, interested in the impact of ubiquitination on patient treatment responses.
• Research content of bioinformatics application, skilled in analyzing high-throughput data of ubiquitination substrates and related pathways. (Purely bioinformatics content is outside the scope of this topic)
The topic of this study covers all tumor types, and the study of non-tumor diseases is not within the scope of this study. Reviews, article, and case reports are the main article types.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.